Study

410 ILCS 460/131-25, under Article 131.

410 ILCS 460/131-25

(410 ILCS 460/131-25)

    Sec. 131-25. Study.     (a) Before July 1, 2022, and on a biennial basis thereafter, the Department, with the assistance of:         (1) the Center for Minority Health Services;         (2) health care providers that treat individuals with     sickle cell disease;        (3) individuals diagnosed with sickle cell disease;         (4) representatives of community-based organizations     that serve individuals with sickle cell disease; and        (5) data collected via newborn screening for sickle     cell disease; shall perform a study to determine the prevalence, impact, and needs of individuals with sickle cell disease and the sickle cell trait in Illinois.

    (b) The study must include the following:         (1) The prevalence, by geographic location, of     individuals diagnosed with sickle cell disease in Illinois.        (2) The prevalence, by geographic location, of     individuals diagnosed as sickle cell trait carriers in Illinois.        (3) The availability and affordability of screening     services in Illinois for the sickle cell trait.         (4) The location and capacity of the following for     the treatment of sickle cell disease and sickle cell trait carriers:             (A) Treatment centers.             (B) Clinics.             (C) Community-based social service organizations.             (D) Medical specialists.

        (5) The unmet medical, psychological, and social     needs encountered by individuals in Illinois with sickle cell disease.        (6) The underserved areas of Illinois for the     treatment of sickle cell disease.         (7) Recommendations for actions to address any     shortcomings in the State identified under this Section.    (c) The Department shall submit a report on the study performed under this Section to the General Assembly.

(Source: P.A. 102-4, eff. 4-27-21.)